Lisata Therapeutics (NASDAQ:LSTA) Stock Rating Reaffirmed by HC Wainwright

Lisata Therapeutics (NASDAQ:LSTA)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They currently have a $15.00 target price on the stock. HC Wainwright’s price objective indicates a potential upside of 343.79% from the stock’s previous close.

Lisata Therapeutics Trading Up 0.6 %

Shares of Lisata Therapeutics stock traded up $0.02 during mid-day trading on Wednesday, reaching $3.38. 8,847 shares of the stock were exchanged, compared to its average volume of 14,612. The company has a market cap of $28.09 million, a price-to-earnings ratio of -1.35 and a beta of 1.24. Lisata Therapeutics has a fifty-two week low of $1.95 and a fifty-two week high of $3.87. The firm has a 50-day simple moving average of $3.17 and a 200 day simple moving average of $3.02.

Lisata Therapeutics (NASDAQ:LSTA) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.08. On average, research analysts predict that Lisata Therapeutics will post -3.08 EPS for the current fiscal year.

Institutional Trading of Lisata Therapeutics

A hedge fund recently raised its stake in Lisata Therapeutics stock. BML Capital Management LLC grew its position in Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 10.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 269,839 shares of the company’s stock after purchasing an additional 26,000 shares during the period. Lisata Therapeutics comprises about 0.6% of BML Capital Management LLC’s portfolio, making the stock its 24th largest position. BML Capital Management LLC owned approximately 3.31% of Lisata Therapeutics worth $737,000 at the end of the most recent reporting period. 8.94% of the stock is currently owned by institutional investors.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.